Leuprolide Acetate (LA)
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Central Precocious Puberty (CPP)
Conditions
Central Precocious Puberty (CPP)
Trial Timeline
Oct 24, 2018 → Nov 29, 2023
NCT ID
NCT03695237About Leuprolide Acetate (LA)
Leuprolide Acetate (LA) is a phase 3 stage product being developed by AbbVie for Central Precocious Puberty (CPP). The current trial status is completed. This product is registered under clinical trial identifier NCT03695237. Target conditions include Central Precocious Puberty (CPP).
What happened to similar drugs?
4 of 19 similar drugs in Central Precocious Puberty (CPP) were approved
Approved (4) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03695237 | Phase 3 | Completed |
Competing Products
20 competing products in Central Precocious Puberty (CPP)